FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro®(obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients. […]
Last Ebola patient in Democratic Republic of the Congo discharged
https://www.afro.who.int/news/last-ebola-patient-democratic-republic-congo-discharged 19 October 2025 / Bulape – The last Ebola patient in the Democratic Republic of the Congo was discharged today, marking an important milestone in the efforts to end the outbreak. The recovery kicks off a 42-day countdown to declaring the outbreak over if no further cases are confirmed. A total of 19 patients have recovered […]
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Basel, 18 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 44% and 62% in the intention-to-treat (ITT) and ESR1-mutated populations, respectively, compared with standard-of-care endocrine […]
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Basel, 17 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from two phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 and 1 mg) compared with a sham procedure that mimics intravitreal (IVT) injections in people with uveitic macular edema (UME).1 UME is characterised by the […]
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
Basel, 17 October, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gazyva®/Gazyvaro® (obinutuzumab) in combination with mycophenolate mofetil (MMF) for the treatment of adult patients with active Class III or IV, with or without concomitant Class […]
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Annual Meeting in Boston, USA. Following its recent unveiling, SBX is already being recognized by early evaluators in the sequencing community for its combination […]
11 million lives lost each year: urgent action needed on neurological care
14 October 2025 -- Geneva, Seoul -- The World Health Organization (WHO) today warns that less than one in three countries around the world has a national policy to address the growing burden of neurological disorders, responsible for over 11 million deaths globally each year. The WHO’s new Global status report on neurology released today shows that neurological […]
Global health security hangs in the balance in a volatile and uncertain world, report emphasizes
Increased commitment to preparedness and investment in primary health care and risk monitoring essential to protect world from pandemics and other health emergencies 13 October 2025 -- Berlin/Geneva -- A new global report launched today outlines preparedness priorities to protect people worldwide from future pandemics and other health crises; it calls for scaled up investment in […]
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some […]
Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicines
Substandard (contaminated) oral liquid medicines identified in the WHO South-East Asia Region Geneva, 13 October 2025 Alert summary This WHO Medical Product Alert refers to three substandard (contaminated) oral liquid medicines identified in India and reported to WHO on 8 October 2025. The affected products are oral liquid medicines containing active ingredients commonly used to […]
